Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-04-04

Clinical Trial Update: EPANOVA in Crohn's Disease, Study 1 [Phase 3]

View source ↗

Summary

This document reports the completion status of a Phase 3 study of EPANOVA for Crohn's disease conducted by Tillotts Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Epanova (icosapent ethyl)

Snippet

Sponsor: Tillotts Pharma AG | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED